Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:21:22.754Z.
Calculation as of: 2026-10-06T19:21:22.754Z.
Quote observation: 2026-10-06T19:20:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 781bf18d5b555faf6525e3bbfdfcc877af608ad86c98afd042bd19dc8220ce7c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$146.98M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.13M
EV/FCF Ratio
N/A
TTM Avg
13.24x
3Y Avg
34.58x
5Y Avg
28.14x
Market Cap
$146.71M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$152.82M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $149.06M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $148.27M | N/A | 40.01x | 40.01x | 40.01x |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.69M | N/A | N/A | N/A | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $149.89M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $147.81M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.98M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.13M | N/A | 13.24x | 34.58x | 28.14x |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $146.71M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $152.82M | N/A | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $145.85M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
